DelveInsight’s “Gastric Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Gastric Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastric Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastric Neuroendocrine Tumors Overview
Gastric Neuroendocrine Tumors are rare lesions characterized by hypergastrinemia that arise from enterochromaffin-like cells of the stomach. GNETs consist of a heterogeneous group of neoplasms comprising tumor types of varying pathogenesis, histomorphologic characteristics, and biological behavior.
Gastric Neuroendocrine Tumors Epidemiology Insights
The incidence rates of GEP NECs increased consistently from 1.5 cases per 1,000,000 in 1973 to 4.6 cases per 1,000,000.
34% of cases were small cell carcinomas. Certain primary tumor sites such as the anus and esophagus were more predominantly small cell histology.
The presence of metastatic disease at diagnosis ranged from 40 to 76%, with pancreatic NECs most likely to present with metastatic disease.
Click here to learn more about the Gastric Neuroendocrine Tumors Market Landscape
The Report Covers the Gastric Neuroendocrine Tumours Epidemiology Segmented by:
Gastric Neuroendocrine Tumors incident cases
Gastric Neuroendocrine Tumors diagnosed cases
Gastric Neuroendocrine Tumors treatment cases
Gastric Neuroendocrine Tumors prevalent cases
Gastric Neuroendocrine Tumors Market Outlook
The Gastric Neuroendocrine Tumors market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Gastric Neuroendocrine Tumors market trends by analyzing the impact of current Gastric Neuroendocrine Tumors therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Gastric Neuroendocrine Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Gastric Neuroendocrine Tumors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Gastric Neuroendocrine Tumors market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Gastric Neuroendocrine Tumors Market
Novartis
Ipsen
PharmaMar
TiRex Inc
RayZe Bio Inc
Pfizer
And many others
Gastric Neuroendocrine Tumors Therapies Covered and Analyzed in the Report:
Ribociclib
Satoreotide trizoxetan
Octreotide LAR
Lanreotide ATG
Octreotide LAR
Lutathera
Temozolomide
And many others
Learn more about the Key Companies and Emerging Therapies in the Gastric Neuroendocrine Tumors Market
Table of Contents
Key Insights
Gastric Neuroendocrine Tumours Introduction
Executive Summary of Gastric Neuroendocrine Tumours
Disease Background and Overview
Epidemiology and patient population
Gastric Neuroendocrine Tumours Emerging Therapies
Gastric Neuroendocrine Tumours Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Gastric Neuroendocrine Tumors Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services